| Literature DB >> 27668936 |
Peter Rusert1, Roger D Kouyos1,2, Claus Kadelka1,2, Hanna Ebner1, Merle Schanz1, Michael Huber1, Dominique L Braun1,2, Nathanael Hozé3, Alexandra Scherrer1,2, Carsten Magnus1, Jacqueline Weber1, Therese Uhr1, Valentina Cippa1, Christian W Thorball4,5, Herbert Kuster1,2, Matthias Cavassini6, Enos Bernasconi7, Matthias Hoffmann8, Alexandra Calmy9, Manuel Battegay10, Andri Rauch11, Sabine Yerly12, Vincent Aubert13, Thomas Klimkait14, Jürg Böni1, Jacques Fellay4,5, Roland R Regoes4, Huldrych F Günthard1,2, Alexandra Trkola1.
Abstract
Broadly neutralizing antibodies (bnAbs) are a focal component of HIV-1 vaccine design, yet basic aspects of their induction remain poorly understood. Here we report on viral, host and disease factors that steer bnAb evolution using the results of a systematic survey in 4,484 HIV-1-infected individuals that identified 239 bnAb inducers. We show that three parameters that reflect the exposure to antigen-viral load, length of untreated infection and viral diversity-independently drive bnAb evolution. Notably, black participants showed significantly (P = 0.0086-0.038) higher rates of bnAb induction than white participants. Neutralization fingerprint analysis, which was used to delineate plasma specificity, identified strong virus subtype dependencies, with higher frequencies of CD4-binding-site bnAbs in infection with subtype B viruses (P = 0.02) and higher frequencies of V2-glycan-specific bnAbs in infection with non-subtype B viruses (P = 1 × 10-5). Thus, key host, disease and viral determinants, including subtype-specific envelope features that determine bnAb specificity, remain to be unraveled and harnessed for bnAb-based vaccine design.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27668936 DOI: 10.1038/nm.4187
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440